Table 4.
Multivariate analysis of variables predicting Disease-free-survival (DFS) in a cohort of 65 patients with GATA2 deficiency and 404 patients without known predisposition syndrome.
| Relative risk | 95 CI | P | |
|---|---|---|---|
| Age at HSCT | |||
| ≥12 yrs. vs. <12 yrs. | 1.1 | [0.7–1.6] | n.s. |
| GATA2 mutated | |||
| yes vs. no | 0.7 | [0.4–1.3] | n.s. |
| Karyotype | |||
| Monosomy 7 vs. normal | 22 | [1.2–3.9] | <0.01 |
| Other vs. normal | 1.6 | [0.8–3.8] | n.s. |
| Other vs. monosomy 7 | 0.7 | [0.4-1.3] | n.s. |
| Most advanced MDS type prior to HSCT | |||
| MDS-EB vs. RCC | 1.9 | [1.0–3.4] | 0.04 |
| MDS-EBt/ MDR-AML vs. RCC | 3.7 | [2.2–6.3] | <0.01 |
| MDS-EBt/MDR-AML vs. MDS-EB | 2.0 | [1.2–3.4] | 0.01 |
CI confidence interval, MDS myelodysplastic syndrome, HSCT hematopoietic stem cell transplantation, MDS-EB MDS with excess blasts, MDS-EBt MDS with excess blasts in transformation, RCC refractory cytopenia of childhood, MDR-AML MDS-related acute myeloid leukemia, yrs years.